Aurobindo Pharma shares rally as US FDA approves Beclomethasone Dipropionate HFA Inhalation Aerosol
Why did Aurobindo Pharma Ltd shares fall today?
Today, Aurobindo Pharma Ltd shares declined by 0.47% to ₹1,667.65 as of 01:39 PM on Tuesday. This drop occurred despite the company announcing a significant positive development from the US Food and Drug Administration (FDA), which has been a key focus for investors tracking pharmaceutical stocks.
The news, detailed in a press release submitted to the National Stock Exchange and BSE, confirms that Aurobindo Pharma has received final FDA approval for Beclomethasone Dipropionate HFA Inhalation Aerosol in two dosage strengths: 40 mcg and 80 mcg. This medication is commonly used to manage and prevent respiratory issues like asthma, and the approval enables the company to introduce and sell this product in the United States market, potentially boosting its revenue streams.
Even with this favorable regulatory milestone, Aurobindo Pharma's shares experienced a minor fall. Such movements can sometimes happen in the stock market when investors engage in profit-taking after positive news, or due to broader market conditions that overshadow individual company updates. For now, the approval strengthens the company's product portfolio, but today's price change reflects the immediate market reaction.
What does Aurobindo Pharma Ltd do?
Aurobindo Pharma Limited is a pharmaceutical company that develops and markets healthcare products. Its activities include obtaining regulatory approvals from authorities like the USFDA for pharmaceutical formulations, such as the Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths.
The company operates with corporate and registered offices in Hyderabad, Telangana, India. It is listed on the National Stock Exchange of India Limited and BSE Limited under the respective company codes AUROPHARMA and 524804.
Aurobindo Pharma Ltd Financials
In CroresAurobindo Pharma Ltd's financials show a positive upward trend between the March and June 2026 quarters. The company's revenue increased from ₹8,751.5 crore in March 2026 to ₹9,105.82 crore in June 2026, reflecting growth. Similarly, its profit also expanded during this period, rising from ₹921.26 crore to ₹1,032.56 crore. The data indicates that both the top-line revenue and bottom-line profit of the company grew sequentially in the reported periods.
Aurobindo Pharma Ltd Shareholding Pattern
Promoter holding stands at 51.88% of the total share capital. Foreign Institutional Investors (FIIs) hold 16.38% stake in the company, while Domestic Institutional Investors (DIIs) hold 25.05%. Public shareholders hold the remaining 6.68% stake in Aurobindo Pharma Ltd.
Aurobindo Pharma Ltd FAQs
Q: Why did Aurobindo shares fall 0.47% today?
Submission of Press Release that is being issued in connection with receipt of US FDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol , 40 mcg and 80 mcg.. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Aurobindo Pharma Ltd?
As per the latest data, promoters hold 51.88% stake in Aurobindo Pharma Ltd, while FII holding stands at 16.38%. Domestic institutional investors hold 25.05%, and public shareholders account for 6.68% of the equity.
Q: What is the current stock price of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd shares are currently trading at ₹1667.65, recording a decline of 0.47% from the previous close.
Q: What is the market capitalization of Aurobindo Pharma Ltd?
The company currently has a market capitalization of ₹97004.98 crore, reflecting its valuation in the Indian equity market.